Neovasc Inc. (NVCN) News

Neovasc Inc. (NVCN): $29.49

-0.39 (-1.31%)

POWR Rating

Component Grades













Filter NVCN News Items

NVCN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NVCN News Highlights

  • For NVCN, its 30 day story count is now at 2.
  • Over the past 3 days, the trend for NVCN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest NVCN News From Around the Web

Below are the latest news stories about NEOVASC INC that investors may wish to consider to help them evaluate NVCN as an investment opportunity.

Neovasc's (TSE:NVCN) investors will be pleased with their solid 171% return over the last year

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. On the other hand, if you...

Yahoo | March 9, 2023

Neovasc Shareholders Approve Acquisition by Shockwave Medical

Vancouver, British Columbia--(Newsfile Corp. - March 6, 2023) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the "Shares") by Shockwave Medical, Inc. ("Shockwave") by way of a statutory plan of arrangement

Yahoo | March 6, 2023

Neovasc Announces German Reimbursement Renewal

VANCOUVER and MINNEAPOLIS, Feb. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc, Inc. (“Neovasc” or “the Company”) (NASDAQ , TSX : NVCN) today announced the German Institute for the Hospital Remuneration System (“InEK”) has awarded the Neovasc Reducer™ (“Reducer”), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation for 2023. New examination and treatment methods (NUBs) are comprised of novel and innovative medicines, medical products and procedure

Yahoo | February 1, 2023

5 big deal reports: Sun Pharma’s $576M pact for Concert Pharma

By Davit Kirakosyan

Yahoo | January 22, 2023

Shockwave Medical's (SWAV) New Buyout to Boost Patient Outcome

Shockwave Medical's (SWAV) latest acquisition is expected to serve a wider patient pool.

Yahoo | January 18, 2023

Dow Dinged As Big Bank Earnings Weigh

A round of earnings from the banking sector is weighing today, stifling Wall Street's early 2023 momentum. | January 17, 2023

Shockwave Medical Seeks To Bolster Its Cardiovascular Disease Portfolio With Neovasc Acquisition

Shockwave Medical Inc (NASDAQ: SWAV) has agreed to acquire Neovasc Inc (NASDAQ: NVCN) for an upfront cash payment of $27.25 per share, corresponding to an enterprise value of approximately $100 million. The upfront cash consideration represents a 27% and 68% premium to the closing price and 30-day VWAP, respectively, of Neovasc's common shares on Jan. 13, 2023. Neovasc shareholders will also receive a potential deferred payment in the form of a non-tradable contingent value right (CVR), entitlin

Yahoo | January 17, 2023

Shockwave Medical to Acquire Neovasc

Vancouver, British Columbia--(Newsfile Corp. - January 17, 2023) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Company has entered into a binding agreement (the "Arrangement Agreement") with Shockwave Medical, Inc. ("Shockwave"), whereby Shockwave has agreed to acquire all of the issued and outstanding common shares (the "Common Shares") of the Comp

Yahoo | January 17, 2023

IIROC Trade Resumption - NVCN

Trading resumes in:

Yahoo | January 17, 2023

IIROC Trading Halt - NVCN

The following issues have been halted by IIROC:

Yahoo | January 17, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7727 seconds.